Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

FDA Approves Spectranetics' Laser Catheterfor Angioplasty Use

Photonics.com
Feb 2000
COLORADO SPRINGS, Colo., Feb. 18 -- The US Food and Drug Administration (FDA) has approved Spectranetics Corp.'s pre-market approval supplement to market a new line of single-use catheters for laser-based coronary angioplasty procedures. Spectranetics' new Vitesse Cos catheters are designed to achieve greater debulking in a blocked coronary artery than was possible using earlier generation catheters.
According to Spectranetics, laboratory tests showed the Vitesse Cos capable of improving debulking efficiency -- the dissolving of tissue blocking an artery -- by up to 62 percent over levels achieved with earlier generations of catheters. In developing the Vitesse Cos, the company used a proprietary engineering process to precisely bundle the optical fibers that conduct the laser's light pulses to the tissue blockage being treated.

News & Featureslasers

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.